Preliminary results showed that median progression-free survival was 22.3 months with KMP compared with 22.1 months with VMP. Though not yet mature, there was also no statistically significant difference in overall survival between the 2 treatment arms.

The adverse events observed in the KMP arm were consistent with previous reports of carfilzomib's safety profile. Nearly 75% of patients in the KMP arm experienced grade 3 or worse adverse events, versus about 76% in the VMP arm. Substantially more patients (35.1%) of patients in the VMP arm reported grade 2 or worse peripheral neuropathy than those who received KMP (2.5%).

"Based on studies in the Kyprolis label, including the ENDEAVOR study, a head-to-head comparison of Kyprolis to Velcade in patients with relapsed or refractory multiple myeloma, we know Kyprolis to be a major advance in proteasome inhibitor therapy," Sean E. Harper, MD, executive vice president of Research and Development at Amgen, stated in a press release. "The CLARION results, generated in the context of a melphalan-containing regimen, are disappointing, especially given the robust data we've seen in the second-line setting."

Investigators are comparing the efficacy and safety of carfilzomib with that of bortezomib, in combination with lenalidomide and dexamethasone, among newly diagnosed patients with multiple myeloma as part of the phase 3 ENDURANCE trial (Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma; ClinicalTrials.gov Identifier: NCT01863550). The study is recruiting patients nationwide.

Although the effectiveness and safety of bortezomib-based therapy for patients with R/R MM has been demonstrated in phase 2 and phase 3 clinical trials, data collected from real-world settings appear ...

CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients.

Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.